Anti-interleukin-33 antibodies and uses thereof 机翻标题: 暂无翻译,请尝试点击翻译按钮。

公开号/公开日
WO2016077381 A1 2016-05-19 [WO201677381]WO2016077381 A8 2016-06-30 [WO201677381] / 2016-05-192016-06-30
申请号/申请日
2015WO-US60008 / 2015-11-10
发明人
HASS PHILIP E;HAZEN MEREDITH;HSIAO YI-CHUN;KHOSLA RAJITA;NAKAMURA GERALD R;SESHASAYEE DHAYA;VAN LOOKEREN CAMPAGNE MENNO;XI HONGKANG;ZHAI WENWU;BEVERS JACK III;CHIANG NANCY;
申请人
GENENTECH;HOFFMANN LA ROCHE;
主分类号
IPC分类号
C07K-016/24
摘要
(WO201677381) The invention provides interleukin-33 (IL-33) antibodies and methods of using the same.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2014US-62077876 2014-11-10 2015US-62165732 2015-05-22
主权利要求
(WO201677381)  1 . An isolated antibody that specifically binds both human and cynomolgus monkey (cyno) interleukin-33 (IL-33) with a KD of about 500 pM or lower.  37. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the aminoacid sequence of SFSXiS (SEQ ID NO: 62), wherein is Met, Leu, or Val; (b) an HVR-H2 comprising the aminoacid sequence of TISGGKTFTDYVDX^KG (SEQ ID NO: 63), wherein is Ser or Ala; (c) an HVR-H3 comprising the aminoacid sequence of ANYGX1X2FFEV (SEQ ID NO: 64), wherein XT is Asn or Asp, and X2 is Trp or Phe; (d) an HVR-L1 comprising the aminoacid sequence of RASESVAKYGLSLLN (SEQ ID NO: 4) ; (e) an HVR-L2 comprising the aminoacid sequence of AASNRGS (SEQ ID NO: 5) ; and (f) an HVR-L3 comprising the aminoacid sequence of QQSKEVPFT (SEQ ID NO: 6).  39. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising (a) a heavy chain variable (VH) domain comprising an aminoacid sequence having at least 95% sequence identity to the aminoacid sequence of SEQ ID NO: 36; (b) a light chain variable (VL) domain comprising an aminoacid sequence having at least 95% sequence identity to the aminoacid sequence of SEQ ID NO: 37; or (c) a VH domain as in (a) and a VL domain as in (b).  44. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising (a) a VH domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 36 and (b) a VL domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 37.  49. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising (a) a VH domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 38 and (b) a VL domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 39.  54. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising (a) a VH domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 40 and (b) a VL domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 41 .  55. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the aminoacid sequence of SSIFYWG (SEQ ID NO: 65) ; (b) an HVR-H2 comprising the aminoacid sequence of SIYYSG RTYYN PXT LKS (SEQ ID NO: 90), wherein is Ser or Ala; (c) an HVR-H3 comprising the aminoacid sequence of AGGLYNWNDESFSFYMDV (SEQ ID NO: 68) ; (d) an HVR-L1 comprising the aminoacid sequence of RASQSFSSSYLA (SEQ ID NO: 69) ; (e) an HVR-L2 comprising the aminoacid sequence of GASSRAT (SEQ ID NO: 70) ; and (f) an HVR-L3 comprising the aminoacid sequence of QQYDRSPLT (SEQ ID NO: 71 ).  58. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising (a) a heavy chain variable (VH) domain comprising an aminoacid sequence having at least 95% sequence identity to the aminoacid sequence of SEQ ID NO: 84; (b) a light chain variable (VL) domain comprising an aminoacid sequence having at least 95% sequence identity to the aminoacid sequence of SEQ ID NO: 85; or (c) a VH domain as in (a) and a VL domain as in (b).  63. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising (a) a VH domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 84 and (b) a VL domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 85.  67. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising (a) a VH domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 86 and (b) a VL domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 87.  72. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising (a) a VH domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 88 and (b) a VL domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 89.  73. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the aminoacid sequence of .NU..UPSILON..CHI.GREEK CAPITAL LETTER IOTA WITH DIALYTIKA .MU..NU. (SEQ ID NO: 97), wherein X^ is Trp, Phe, or Tyr; (b) an HVR-H2 comprising the aminoacid sequence of EITLKFNX1YX2THYAESVKG (SEQ ID NO: 98), wherein X^ is Asn, Asp, Ser, or Ala, and X2 is Ser or Ala; (c) an HVR-H3 comprising the aminoacid sequence of RNYGXiX2YINV (SEQ ID NO: 99), wherein is Asp or Asn, and X2 is Trp or Phe; (d) an HVR-L1 comprising the aminoacid sequence of RASESVDKFGXiSFLN (SEQ ID NO: 1 00), wherein X^ is Met, Val, or Leu; (e) an HVR-L2 comprising the aminoacid sequence of VASSQGS (SEQ ID NO: 1 13) ; and (f) an HVR-L3 comprising the aminoacid sequence of QQSKDIPYT (SEQ ID NO: 1 14).  77. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising (a) a heavy chain variable (VH) domain comprising an aminoacid sequence having at least 95% sequence identity to the aminoacid sequence of SEQ ID NO: 134; (b) a light chain variable (VL) domain comprising an aminoacid sequence having at least 95% sequence identity to the aminoacid sequence of SEQ ID NO: 135; or (c) a VH domain as in (a) and a VL domain as in (b).  82. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising (a) a VH domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 134 and (b) a VL domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 135.  83. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising (a) a heavy chain variable (VH) domain comprising an aminoacid sequence having at least 95% sequence identity to the aminoacid sequence of SEQ ID NO: 136; (b) a light chain variable (VL) domain comprising an aminoacid sequence having at least 95% sequence identity to the aminoacid sequence of SEQ ID NO: 137; or (c) a VH domain as in (a) and a VL domain as in (b).  88. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising (a) a VH domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 136 and (b) a VL domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 137.  93. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising (a) a VH domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 138 and (b) a VL domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 139.  94. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the aminoacid sequence of KFWMN (SEQ ID NO: 158) ; (b) an HVR-H2 comprising the aminoacid sequence of EIRLX1X2INYVKDYAESVKG (SEQ ID NO: 161 ), wherein is Asn or Ser, and X2 is Ser or Ala; (c) an HVR-H3 comprising the aminoacid sequence of RNYGNWFFEI (SEQ ID NO: 160) ; (d) an HVR-L1 comprising the aminoacid sequence of RASESVDRYGISFMN (SEQ ID NO: 164) ; (e) an HVR-L2 comprising the aminoacid sequence of AASNQGS (SEQ ID NO: 1 65) ; and (f) an HVR-L3 comprising the aminoacid sequence of QHSKEVPYT (SEQ ID NO: 166).  98. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising (a) a heavy chain variable (VH) domain comprising an aminoacid sequence having at least 95% sequence identity to the aminoacid sequence of SEQ ID NO: 183; (b) a light chain variable (VL) domain comprising an aminoacid sequence having at least 95% sequence identity to the aminoacid sequence of SEQ ID NO: 1 84; or (c) a VH domain as in (a) and a VL domain as in (b).  103. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising (a) a VH domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 183 and (b) a VL domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 184.  104. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising (a) a heavy chain variable (VH) domain comprising an aminoacid sequence having at least 95% sequence identity to the aminoacid sequence of SEQ ID NO: 185; (b) a light chain variable (VL) domain comprising an aminoacid sequence having at least 95% sequence identity to the aminoacid sequence of SEQ ID NO: 186; or (c) a VH domain as in (a) and a VL domain as in (b).  124. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising (a) a VH domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 216 and (b) a VL domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 217.  125. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising (a) a heavy chain variable (VH) domain comprising an aminoacid sequence having at least 95% sequence identity to the aminoacid sequence of SEQ ID NO: 21 8; (b) a light chain variable (VL) domain comprising an aminoacid sequence having at least 95% sequence identity to the aminoacid sequence of SEQ ID NO: 219; or (c) a VH domain as in (a) and a VL domain as in (b).  130. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising (a) a VH domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 218 and (b) a VL domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 219. 133. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising (a) a VH domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 220 and (b) a VL domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 219.  134. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the aminoacid sequence of SYWIN (SEQ ID NO: 222) ; (b) an HVR-H2 comprising the aminoacid sequence of RIAPGSGFISYNELFKD (SEQ ID NO: 223) ; (c) an HVR-H3 comprising the aminoacid sequence of EFYYGSFYGGFAY (SEQ ID NO: 224) ; (d) an HVR-L1 comprising the aminoacid sequence of HASQN IHVWLS (SEQ ID NO: 225) ; (e) an HVR-L2 comprising the aminoacid sequence of KASTLHT (SEQ ID NO: 226) ; and (f) an HVR-L3 comprising the aminoacid sequence of QQGQSSPLT (SEQ ID NO: 227).  135. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising (a) a heavy chain variable (VH) domain comprising an aminoacid sequence having at least 95% sequence identity to the aminoacid sequence of SEQ ID NO: 236; (b) a light chain variable (VL) domain comprising an aminoacid sequence having at least 95% sequence identity to the aminoacid sequence of SEQ ID NO: 237; or (c) a VH domain as in (a) and a VL domain as in (b).  140. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising (a) a VH domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 236 and (b) a VL domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 237.  141 . An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising (a) a heavy chain variable (VH) domain comprising an aminoacid sequence having at least 95% sequence identity to the aminoacid sequence of SEQ ID NO: 246; (b) a light chain variable (VL) domain comprising an aminoacid sequence having at least 95% sequence identity to the aminoacid sequence of SEQ ID NO: 247; or (c) a VH domain as in (a) and a VL domain as in (b).  146. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising (a) a VH domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 246 and (b) a VL domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 247.  147. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the aminoacid sequence of GSAX^ (SEQ ID NO: 248), wherein X^ is Met or lie; (b) an HVR-H2 comprising the aminoacid sequence of RIRSX1X2NX3YATX4YX5ASVKG (SEQ ID NO: 249), wherein X^ is Arg or Lys, X2 is Asn, Thr, or Gly, X3 is Asn or Ser, X4 is Ala or Glu, and X5 is Ala or Asp; (c) an HVR-H3 comprising the aminoacid sequence of X1X2X3X4PFDY (SEQ ID NO: 250), wherein is Leu or Gin, X2 is Gin, Gly, or Phe, X3 is Gin or Gly, and X4 is Pro or Asp; (d) an HVR-L1 comprising the aminoacid sequence of RASQG IRNDLD (SEQ ID NO: 251 ) ; (e) an HVR-L2 comprising the aminoacid sequence of AASSLQS (SEQ ID NO: 252) ; and (f) an HVR-L3 comprising the aminoacid sequence of LQHX^YPXsT (SEQ ID NO: 253), wherein XT is Asp or Ser, X2 is Ser or lie, and X3 is Leu or Pro.  156. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising (a) a VH domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 282 and (b) a VL domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 283.  157. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising (a) a heavy chain variable (VH) domain comprising an aminoacid sequence having at least 95% sequence identity to the aminoacid sequence of SEQ ID NO: 284; (b) a light chain variable (VL) domain comprising an aminoacid sequence having at least 95% sequence identity to the aminoacid sequence of SEQ ID NO: 285; or (c) a VH domain as in (a) and a VL domain as in (b).  162. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising (a) a VH domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 284 and (b) a VL domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 285.  163. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising (a) a heavy chain variable (VH) domain comprising an aminoacid sequence having at least 95% sequence identity to the aminoacid sequence of SEQ ID NO: 286; (b) a light chain variable (VL) domain comprising an aminoacid sequence having at least 95% sequence identity to the aminoacid sequence of SEQ ID NO: 287; or (c) a VH domain as in (a) and a VL domain as in (b).  168. An isolated antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising (a) a VH domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 286 and (b) a VL domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 287.  169. An isolated antibody that specifically binds IL-33, wherein the antibody comprises (a) a heavy chain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 288 and (b) a light chain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 289.  170. An isolated antibody that specifically binds IL-33, wherein the antibody comprises (a) a heavy chain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 290 and (b) a light chain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 291 . 171 . An isolated antibody that specifically binds IL-33, wherein the antibody comprises (a) a heavy chain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 292 and (b) a light chain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 293.  172. An isolated antibody that specifically binds IL-33, wherein the antibody comprises (a) a heavy chain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 294 and (b) a light chain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 295.  222. An isolated antibody that specifically binds both IL-33 and IL-13, wherein the antibody comprises a first binding domain that specifically binds IL-33 comprising the following six HVRs: (a) an HVR-H1 comprising the aminoacid sequence of SSIFYWG (SEQ ID NO: 65) ; (b) an HVR-H2 comprising the aminoacid sequence of SIYYSGRTYYNPSLKS (SEQ ID NO: 66) ; (c) an HVR-H3 comprising the aminoacid sequence of AGGLYNWNDESFSFYMDV (SEQ ID NO: 68) ; (d) an HVR-L1 comprising the aminoacid sequence of RASQSFSSSYLA (SEQ ID NO: 69) ; (e) an HVR-L2 comprising the aminoacid sequence of GASSRAT (SEQ ID NO: 70) ; and (f) an HVR-L3 comprising the aminoacid sequence of QQYDRSPLT (SEQ ID NO: 71 ) ; and a second binding domain that specifically binds IL-13 comprising the following six HVRs: (a) an HVR-H1 comprising the aminoacid sequence of AYSVN (SEQ ID NO: 296) ; (b) an HVR-H2 comprising the aminoacid sequence of MIWGDGKIVYNSALKS (SEQ ID NO: 297) ; (c) an HVR-H3 comprising the aminoacid sequence of DGYYPYAMDN (SEQ ID NO: 298) ; (d) an HVR-L1 comprising the aminoacid sequence of RASKSVDSYGNSFMH (SEQ ID NO: 299) ; (e) an HVR-L2 comprising the aminoacid sequence of LASNLES (SEQ ID NO: 300) ; and (f) an HVR-L3 comprising the aminoacid sequence of QQNNEDPRT (SEQ ID NO: 301 ).  223. An isolated antibody that specifically binds both IL-33 and IL-13, wherein the antibody comprises a first binding domain that specifically binds IL-33 comprising (a) a VH domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 36 and (b) a VL domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 37, and a second binding domain that specifically binds IL-13 comprising (a) a VH domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 302 and (b) a VL domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 303.  224. An isolated antibody that specifically binds both IL-33 and IL-13, wherein the antibody comprises a first binding domain that specifically binds IL-33 comprising (a) a VH domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 84 and (b) a VL domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 85, and a second binding domain that specifically binds IL-13 comprising (a) a VH domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 302 and (b) a VL domain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 303.  225. An isolated antibody that specifically binds both IL-33 and IL-13, wherein the antibody comprises: (a) a first heavy chain and a first light chain that specifically bind IL-33, wherein the first heavy chain comprises an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 306 and the first light chain comprises an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 307, and (b) a second heavy chain and a second light chain that specifically bind IL-13, wherein the second heavy chain comprises an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 304 and the second light chain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 305.  226. An isolated antibody that specifically binds both IL-33 and IL-13, wherein the antibody comprises: (a) a first heavy chain and a first light chain that specifically bind IL-33, wherein the first heavy chain comprises an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 308 and the first light chain comprises an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 309, and (b) a second heavy chain and a second light chain that specifically bind IL-13, wherein the second heavy chain comprises an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 304 and the second light chain comprising an aminoacid sequence having at least 99% sequence identity to the aminoacid sequence of SEQ ID NO: 305.  297. Use of a bispecific antibody that specifically binds both IL-33 and Factor D or an antigen-binding antibody fragment thereof in the manufacture of a medicament for treating GA.  305. Use of a bispecific antibody that specifically binds both IL-33 and VEGF or an antigen-binding antibody fragment thereof in the manufacture of a medicament for treating wet AMD.  335. A method of treating GA in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a bispecific antibody that specifically binds both IL-33 and Factor D, or an antigen-binding antibody fragment thereof.  339. A method of treating GA, AMD, DR, PCV, or ROP in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a bispecific antibody that specifically binds both IL-33 and HtrA1 , or an antigen-binding antibody fragment thereof.  343. A method of treating wet AMD in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a bispecific antibody that specifically binds both IL-33 and VEGF or an antigen-binding antibody fragment thereof.
法律状态
(WO201677381) LEGAL DETAILS FOR WO2016077381  Actual or expected expiration date=2018-11-22    Legal state=ALIVE    Status=PENDING     Event publication date=2015-11-10  Event code=WO/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=WO WOUS2015060008  Application date=2015-11-10  Standardized application number=2015WO-US60008     Event publication date=2016-05-19  Event code=WO/A1  Event type=Examination events  Published application with search report  Publication country=WO  Publication number=WO2016077381  Publication stage Code=A1  Publication date=2016-05-19  Standardized publication number=WO201677381     Event publication date=2016-06-30  Event code=WO/A8  Event indicator=Pos  Event type=Examination events  International application republished with corrections to front page bibliographic data  Publication country=WO  Publication number=WO2016077381  Publication stage Code=A8  Publication date=2016-06-30  Standardized publication number=WO201677381  LEGAL DETAILS FOR DESIGNATED STATE AU2015346460  Actual or expected expiration date=2035-11-10    Legal state=ALIVE    Status=PENDING   Corresponding cc:  Designated or member state=AU Corresponding appl: AU2015346460  Application date in the designated or member state=2015-11-10   Application number in the designated or member state=2015AU-0346460 Corresponding cc:  Designated or member state=AU Corresponding pat: AU2015346460  Publication stage code in the designated or member state=A1  Publication date in the designated or member state=2017-03-23   Publication number in the designated or member state=AU2015346460    Event publication date=2017-03-23  Event code=WO/ENP  Event type=Entry into national phase  Entry into the national phase in: Corresponding cc:  Designated or member state=AU  LEGAL DETAILS FOR DESIGNATED STATE BR112017009728  Actual or expected expiration date=2035-11-10    Legal state=ALIVE    Status=PENDING   Corresponding cc:  Designated or member state=BR Corresponding appl: BR112017009728  Application date in the designated or member state=2015-11-10   Application number in the designated or member state=2017BR-0009728 Corresponding cc:  Designated or member state=BR Corresponding pat: BR112017009728  Publication stage code in the designated or member state=A1  Publication date in the designated or member state=2017-05-30   Publication number in the designated or member state=BR112017009728    Event publication date=2017-05-30  Event code=WO/REG  Event code=BR/B01A  Event type=Examination events  Reference to a national code Pct publication - request for entry into the national phase Comunicacao da publicacao internacional pct. apresentacao de peticao de requerimento de entrada na fase nacional Corresponding cc:  Designated or member state=BR  LEGAL DETAILS FOR DESIGNATED STATE CA2960297  Actual or expected expiration date=2035-11-10    Legal state=ALIVE    Status=PENDING   Corresponding cc:  Designated or member state=CA Corresponding appl: CA2960297  Application date in the designated or member state=2015-11-10   Application number in the designated or member state=2015CA-2960297 Corresponding cc:  Designated or member state=CA Corresponding pat: CA2960297  Publication stage code in the designated or member state=A1  Publication date in the designated or member state=2016-05-19   Publication number in the designated or member state=CA2960297    Event publication date=2017-03-03  Event code=WO/ENP  Event type=Entry into national phase  Entry into the national phase in: Corresponding cc:  Designated or member state=CA  LEGAL DETAILS FOR DESIGNATED STATE DE  Actual or expected expiration date=2017-05-10    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=DE     Event publication date=2017-05-10  Event code=WO/NENP  Event type=Event indicating Not In Force  Non-entry into the national phase in: Corresponding cc:  Designated or member state=DE  LEGAL DETAILS FOR DESIGNATED STATE EP  Actual or expected expiration date=2035-05-22    Legal state=ALIVE    Status=PENDING   Corresponding cc:  Designated or member state=EP Corresponding appl: EP15797767    Event publication date=2016-06-29  Event code=WO/121  Event type=Designated states  EP: The EPO has been informed by wipo that ep was designated in this application Corresponding cc:  Designated or member state=EP     Event publication date=2017-04-25  Event code=WO/REEP  Event indicator=Pos  Event type=Entry into national phase  Request for entry into the European phase Corresponding cc:  Designated or member state=EP  LEGAL DETAILS FOR DESIGNATED STATE IL251248  Actual or expected expiration date=2035-11-10    Legal state=ALIVE    Status=PENDING   Corresponding cc:  Designated or member state=IL Corresponding appl: IL251248  Application date in the designated or member state=2017-03-19   Application number in the designated or member state=2017IL-0251248 Corresponding cc:  Designated or member state=IL Corresponding pat: IL251248  Publication stage code in the designated or member state=A  Publication date in the designated or member state=2017-05-29   Publication number in the designated or member state=IL-251248    Event publication date=2017-03-19  Event code=WO/WWE  Event indicator=Pos  Event type=Entry into national phase  Wipo information: entry into national phase Corresponding cc:  Designated or member state=IL  LEGAL DETAILS FOR DESIGNATED STATE JP  Actual or expected expiration date=2035-05-22    Legal state=ALIVE    Status=PENDING   Corresponding cc:  Designated or member state=JP Corresponding appl: JP2017525046    Event publication date=2017-05-09  Event code=WO/ENP  Event type=Entry into national phase  Entry into the national phase in: Corresponding cc:  Designated or member state=JP  LEGAL DETAILS FOR DESIGNATED STATE KR20170080604  Actual or expected expiration date=2035-11-10    Legal state=ALIVE    Status=PENDING   Corresponding cc:  Designated or member state=KR Corresponding appl: KR20177012891  Application date in the designated or member state=2015-11-10   Application number in the designated or member state=2017KR-7012891 Corresponding cc:  Designated or member state=KR Corresponding pat: KR20170080604  Publication stage code in the designated or member state=A  Publication date in the designated or member state=2017-07-10   Publication number in the designated or member state=KR20170080604    Event publication date=2017-05-12  Event code=WO/ENP  Event type=Entry into national phase  Entry into the national phase in: Corresponding cc:  Designated or member state=KR  LEGAL DETAILS FOR DESIGNATED STATE SG11201703767X  Actual or expected expiration date=2035-11-10    Legal state=ALIVE    Status=PENDING   Corresponding cc:  Designated or member state=SG Corresponding appl: SG11201703767  Application date in the designated or member state=2015-11-10   Corresponding cc:  Designated or member state=SG Corresponding pat: SG11201703767X  Publication stage code in the designated or member state=A  Publication date in the designated or member state=2017-06-29   Publication number in the designated or member state=SG11201703767X
专利类型码
A1A8
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部